Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001390478-26-000008
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $5,129 | $3,205 |
| General and administrative | 4,123 | 2,858 |
| Total operating expenses | 9,252 | 6,063 |
| Loss from operations | (9,252) | (6,063) |
| Non-operating income: | ||
| Interest income | 845 | 250 |
| Total non-operating income | 845 | 250 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is SELLAS Life Sciences Group, Inc.'s G&A?
- SELLAS Life Sciences Group, Inc. (SLS) reported G&A of $4.12M in Q1 2026.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about SELLAS Life Sciences Group, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude